Global Animal Biotechnology Market Size Likely to Reach at a CAGR of 5.77% By 2034

Global Animal Biotechnology Market size was valued at USD 28.23 Billion in 2025 and is expected to reachUSD 49.25 Billion by 2034, at a CAGR of 5.77% during the forecast period 2025-2034.

Animal Biotechnology Market Overview

The major drivers for the growth of the global animal biotechnology market are increased R&D efforts, increasing prevalence of various diseases among animals, enhanced regulatory supervision, and support efforts from industry players. The increasing number of diseases like cancer among animals is driving the growth of the market. According to estimates made by the Animal Care Foundation, a total of about 6 million new cancer incidents are detected every year among dogs and cats.

Additionally, the American Veterinary Medical Association estimates that 1 out of every 4 dogs will develop cancer at some point, and nearly 50% of dogs aged over 10 years old are likely to develop cancer. Additionally, in farm animals, there has been a significant surge in a host of diseases, along with outbreaks of potentially lethal diseases.

For example, as per a 2024 article in Nature Journal, certain regions of the African continent have an extremely high incidence of foot-and-mouth disease (FMD) among the cattle population. In certain regions, like Ethiopia, its seroprevalence is estimated to be up to 63%. This rise in the spread of various types of diseases makes for the demand for effective diagnosis and treatment products, hence fueling the market.

The market of animal biotechnology is witnessing serious developments in testing & developing new veterinary products utilizing biotechnology to efficiently handle the surging attack of diseases in animals. For example, in August 2024, the United States Secretary of Agriculture, Tom Vilsack, approved a field test for a vaccine that attacks the H5N1 avian influenza virus in cows. This groundbreaking field trial seeks to measure the efficacy of the vaccine in insulating livestock against suspected epidemics.

It will incorporate partnerships with different stakeholders to achieve a thorough assessment and ensure safety. Furthermore, in July 2024, Israel’s Innocan Pharma Corporation filed an Investigational New Animal Drug (INAD) application for its LPT-CBD product with the FDA Center for Veterinary Medicine. LPT-CBD is a cannabidiol product for pain management in animals. The initial tests have indicated encouraging results regarding the drug’s tolerability and efficacy in dogs and other animals.

Based on product, the global animal biotechnology market is segmented by diagnostic tests, biologics, drugs, and reproductive & genetic. The biologics segment had the highest revenue percentage of more than 31.56% in 2024 and is further expected to increase with the highest growth rate of over 10% in the forecast period. The segment’s growth is mainly driven by the growing incidence of animal infections.

These are naturally transferred from animals to humans due to polluted food and water intake or direct contact with infected humans or animals. Vaccination works well to reduce disease burden among animals and has a critical contribution to preventive care and disease prevention.

For example, scientists at Yale University reported in March 2024 that they have created a dog vaccine for cancer treatment in dogs. The vaccine has indicated encouraging results in clinical trials in over 300 dogs. It has been successful in boosting immune response against tumors, raising the survival rate after 12 months from 35% to 60% in some cancers.

Based on applications, the global Animal Biotechnology market is segmented by diagnosis of animal diseases, treatment of animal diseases, preventive care of animals, and other applications. The use of animal preventive care had the largest market share in 2024.

The emergence of pet parents as a key revenue-driven trend for global market expansion as part of the pet humanization phenomenon is essential. Furthermore, an international study conducted by HABRI and Zoetis reveals a direct correlation between the human-animal bond and regular veterinary care. The research involved subjects from the U.S., France, the UK, Spain, Germany, Japan, Brazil, and China.

The research revealed a clear worldwide phenomenon of the enhanced human-pet relationship, and 95% of the respondents asserted that they regard their pets as members of their family. Therefore, such a human-pet bond evolves into enhanced preventive care. The application of product research & development is expected to see exponential growth during the forecast period. In recent years, tremendous efforts worldwide have been made to study new products to diagnose and treat animal health complications better.

Governments, animal welfare societies, animal health firms, and others have been engaged in an ongoing effort to find new avenues to investigate and develop veterinary products like biologics, drugs, diagnostic test kits, genetics, reproductive technologies, and other verticals. For example, in April 2024, the UC Davis Veterinary Genetics Laboratory (VGL) moved into a new laboratory space for its research and educational efforts in veterinary DNA testing and genetics. This lab is supposed to be running at full capacity by 2025 and will be an integral part of the veterinary research & development sector.

The animal biotechnology market is segmented across Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. The North American animal biotechnology market held the highest revenue share of more than 34% in 2024 due to high levels of animal awareness and enhanced healthcare infrastructure.

The availability of healthcare programs and an increase in the number of initiatives towards improving animal health are aspects that are expected to grow the industry’s potential in this region. Additionally, substantial R&D expenditures in the region are expected to grow the animal biotechnology market in North America. In August 2024, Elanco Animal Health spent around USD 130 million expanding its Kansas, U.S. facility by 25,000 sq. ft. and then further developing its veterinary biologics production capacity.

The U.S. animal biotechnology market will reflect prosperous growth following measures implemented by regulatory authorities in designing veterinary R&D processes for the nation. For example, in May 2024, the USFDA revised the regulation for heritable intentional genomic changes (IGAs) in animals. Such an update helps give a risk-based approach towards the simplification of the IGAs approval process to provide more flexibility during their development and commercialization.

Europe’s animal biotechnology industry is already poised to observe promising growth driven by growing efforts on the part of industry moguls to upgrade therapeutic innovation within the veterinary arena via diverse pursuits like partnerships & collaborations, mergers & acquisitions with peers, etc.

For example, in Jan 2024, industry behemoth Ceva purchased Scout Bio, a company specializing in developing and researching biotechnology-based pet treatments. The latter has done this in a bid to advance its biotechnology capabilities through the incorporation of the former’s cutting-edge therapies, such as monoclonal antibodies and gene therapies for animals. This action has the aim of speeding up biotherapeutic advances and healing crippling animal diseases.

The UK animal biotechnology market is likely to witness lucrative growth as other leading market players, following the trend, buy biotechnology-based pet companies to complement their industry size and experience with the latter’s science. For example, Dechra revealed in July 2024 that it was acquiring Invetx Inc.

This was aimed at bolstering Dechra’s line of monoclonal antibody therapeutics for companion animals and capitalizing on Invetx’s novel drug development technologies to enhance treatment alternatives and compliance among veterinarians and pet owners.

Report Scope

CMI has comprehensively analyzed the Global Animal Biotechnology market. The driving forces, restraints, challenges, opportunities, and key trends have been explained in depth to depict an in-depth scenario of the market. Segment-wise market size and market share during the forecast period are duly addressed to portray the probable picture of this Global Animal Biotechnology industry.

The competitive landscape includes key innovators, after-market service providers, market giants, and niche players. These are studied and analyzed extensively concerning their strengths, weaknesses, and value addition prospects. In addition, this report covers key players profiles, market shares, mergers and acquisitions, consequent market fragmentation, new trends, and dynamics in partnerships.

List of the prominent players in the Animal Biotechnology Market:

• Zoetis
• Boehringer Ingelheim
• Merck & Co. Inc.
• Virbac
• Elanco
• Idexx Laboratories
• Dechra Pharmaceuticals
• Heska Corporation
• Indian Immunologicals Ltd
• Hester Biosciences Pvt. Ltd
• Biogénesis Bagó
• Others

The Animal Biotechnology Market is segmented as follows:

By Product Type

• Diagnostic Tests
• Biologics
• Drugs
• Reproductive & Genetic

By Application

• Diagnosis of Animal Diseases
• Treatment of Animal Diseases
• Preventive Care of Animals
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America